Company Overview and News

 
Duke Energy to Provide $38M in Tax Savings to Customers

2018-04-17 zacks
Duke Energy Corp. (DUK - Free Report) will offer a notable $38 million in annual tax savings on electric and natural gas bills for its customers in Ohio and Kentucky, beginning from April and May 2018. The Tax Cuts and Jobs Act that came into effect on Jan 1, 2018, clearly led to this entire bill reduction. Details of Projected Tax Savings In particular, Duke Energy’s customers, residing in Ohio, would save approximately $20 million in annual tax on their electric bills.
Upvote Downvote

 
AGR / Avangrid, Inc. 10-K (Annual Report)

2018-03-26 sec.gov
agr-10k_20171231.htm
Upvote Downvote

 
AGR / Avangrid, Inc. FORM 8-K (Current Report)

2018-03-16 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
AGR / Avangrid, Inc. FORM 8-K (Current Report)

2018-03-15 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
AGR / Avangrid, Inc. NT 10-K

2018-03-02 sec.gov
NT 10-K SEC FILE NUMBER 001-37660
Upvote Downvote

 
AGR / Avangrid, Inc. AMENDMENT NO. 1 TO FORM 8-K (Current Report)

2018-02-22 sec.gov
Amendment No. 1 to Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K/A     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2018 (February 20, 2018)     Avangrid, Inc. (Exact name of registrant as specified in its charter)       New York   001-37660   14-1798693 (State or other jurisdiction of incorporation)   (Commission File No.
Upvote Downvote

 
AGR / Avangrid, Inc. FORM 8-K (Current Report)

2018-02-21 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2018     Avangrid, Inc. (Exact name of registrant as specified in its charter)       New York   001-37660   14-1798693 (State or other jurisdiction of incorporation)   (Commission File No.
Upvote Downvote

 
Avangrid's (AGR) CEO James Torgerson on Q4 2017 Results and Investor Day - Earnings Call Transcript

2018-02-21 seekingalpha
Avangrid, Inc. (NYSE:AGR) Q4 2017 Earnings and Investor Day Conference Call February 20, 2018 8:00 AM ET
Upvote Downvote

 
Avangrid, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-02-20 seekingalpha
The following slide deck was published by Avangrid, Inc. in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
AGR / Avangrid, Inc. 8-K (Current Report)

2018-02-20 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2018     Avangrid, Inc. (Exact name of registrant as specified in its charter)   New York   001-37660   14-1798693 (State or other jurisdiction of incorporation)   (Commission File No.
Upvote Downvote

 
AGR / Avangrid, Inc. 8-K (Current Report)

2018-02-20 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2018     Avangrid, Inc. (Exact name of registrant as specified in its charter)       New York (State or other jurisdiction of incorporation)   001-37660 (Commission File No.
Upvote Downvote

 
AGR / Avangrid, Inc. FORM 8-K (Current Report)

2018-02-20 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2018     Avangrid, Inc. (Exact name of registrant as specified in its charter)       New York   001-37660   14-1798693 (State or other jurisdiction of incorporation)   (Commission File No.
Upvote Downvote

 
AGR / Avangrid, Inc. 8-K (Current Report)

2018-02-01 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2018     Avangrid, Inc. (Exact name of registrant as specified in its charter)       New York   001-37660   14-1798693 (State or other jurisdiction of incorporation)   (Commission File No.
Upvote Downvote

 
AGR / Avangrid, Inc. ER

2018-01-29 sec.gov
Mail Stop 3561 December 19, 2017 Richard J. Nicholas Chief Financial Officer Avangrid, Inc. 180 Marsh Hill Road Orange, Connecticut 06477 Re: Avangrid, Inc. Form 10-K for Fiscal Year Ended December 31, 2016 Filed March 10, 2017 Form 8-K Filed October 24, 2017 File No. 1-37660 Dear Mr. Nicholas: We have limited our review of your filings to the financial statements and related disclosures and have the following comments.
Upvote Downvote

 
AGR / Avangrid, Inc. ESP

2018-01-29 sec.gov
CORRESP    Richard J. Nicholas Senior Vice President – Chief Financial Officer December 21, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: William H. Thompson, Accounting Branch Chief   Re: Avangrid, Inc.   Form 10-K for Fiscal Year Ended December 31, 2016   Filed March 10, 2017   Form 8-K Filed October 24, 2017   File No.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 05351W103